Registre simple
dc.contributor |
Universitat de Vic - Universitat Central de Catalunya. Càtedra de la Sida i Malalties Relacionades |
|
dc.contributor.author |
Santos, José R.
|
|
dc.contributor.author |
Blanco, José Luis
|
|
dc.contributor.author |
Masiá, Mar
|
|
dc.contributor.author |
Gutiérrez, Félix
|
|
dc.contributor.author |
Pérez-Elías, María Jesús
|
|
dc.contributor.author |
Iribarren, José Antonio
|
|
dc.contributor.author |
Force, Lluis
|
|
dc.contributor.author |
Antela, Antonio
|
|
dc.contributor.author |
Knobel, Hernando
|
|
dc.contributor.author |
Salavert, Miquel
|
|
dc.contributor.author |
López Bernaldo de Quirós, Juan Carlos
|
|
dc.contributor.author |
Pino, Maria
|
|
dc.contributor.author |
Paredes, Roger
|
|
dc.contributor.author |
Clotet, Bonaventura
|
|
dc.date.accessioned |
2016-01-19T10:39:06Z |
|
dc.date.available |
2016-01-19T10:39:06Z |
|
dc.date.created |
2015 |
|
dc.date.issued |
2015 |
|
dc.identifier.citation |
Santos J.R., Blanco J.L., Masiá M., Gutiérrez F., Pérez-Elías M.J., Iribarren J.A., et al. (2015). Virological failure to raltegravir in spain: Incidence, prevalence and clinical consequences. Journal of Antimicrobial Chemotherapy, 70(11), 3087-3095. |
ca_ES |
dc.identifier.issn |
1460-2091 |
|
dc.identifier.uri |
http://hdl.handle.net/10854/4405 |
|
dc.description.abstract |
Objectives: The objective of this study was to evaluate the incidence, prevalence and clinical consequences of
virological failure (VF) to raltegravir-based regimens in Spain.
Methods: A multicentre, retrospective, observational study was performed in 10 tertiary hospitals (January 2006
to June 2013). The study included HIV-1-infected patients with loss of virological suppression (LVS; two consecutive
HIV-1 RNA ≥50 copies/mL) while receiving raltegravir. VF and low-level viraemia (LLV) were defined as two
consecutive HIV-1 RNA ≥200 copies/mL and 50 to ,200 copies/mL, respectively. Integrase strand-transfer
inhibitor resistance was investigated at LVS. During the 48 weeks following LVS, recorded data included clinical
characteristics, treatment discontinuations, AIDS-associated events and deaths. Effectiveness of therapy following
LVS was evaluated by ITT and PP. Multivariate regression was used to assess predictors of efficacy.
Results: Of the 15009 HIV-infected patients in participating centres, 2782 (18.5%) had received raltegravirbased
regimens. Of those, 192 (6.9%), 125 (4.5%) and 67 (2.4%) experienced LVS, VF and LLV, respectively.
The incidence of VF was 1.8 (95% CI, 1.5–2.1) per 100 patients/year. The prevalence of VF was 4.5% (95% CI,
3.8%–5.3%). Integrase-associated mutations were found in 78.8% of patients with integrase genotyping results
available. High-level resistance to dolutegravir was not observed. Salvage therapy failed in 34.1% of patients;
progression to AIDS/death occurred in 8.3% during the first year following LVS. The latter was associated with
intravenous drug use, time on raltegravir and lower CD4+ count nadir in patients who started raltegravirbased
treatments as salvage regimens.
Conclusions: VF with raltegravir is infrequent, but often associated with major clinical complications in
treatment-experienced patients. |
ca_ES |
dc.format |
application/pdf |
|
dc.format.extent |
9 p. |
ca_ES |
dc.language.iso |
eng |
ca_ES |
dc.publisher |
Oxford University Press |
ca_ES |
dc.rights |
Tots els drets reservats |
ca_ES |
dc.rights |
(c) Oxford University Press |
|
dc.subject.other |
Sida -- Tractament |
ca_ES |
dc.title |
Virological failure to raltegravir in spain: Incidence, prevalence and clinical consequences |
ca_ES |
dc.type |
info:eu-repo/semantics/article |
ca_ES |
dc.identifier.doi |
https://doi.org/10.1093/jac/dkv205 |
|
dc.rights.accessRights |
info:eu-repo/semantics/closedAccess |
ca_ES |
dc.type.version |
info:eu-repo/publishedVersion |
ca_ES |
dc.indexacio |
Indexat a SCOPUS |
ca_ES |
dc.indexacio |
Indexat a WOS |
|
Text complet d'aquest document
Registre simple